Overview
NASTAD is a non-partisan, non-profit association that supports public health officials who administer HIV and hepatitis programs in the U.S. and around the world. It strengthens government public health infrastructure, builds community partnerships, and uses data analysis, research, and policy guidance to improve prevention and treatment. It funds targeted projects like the CDC-supported Patient Navigation for People Who Use Drugs and runs training programs such as HepTAC VLC to boost viral hepatitis prevention and surveillance. Its goal is to expand access to prevention and care, inform policy, and improve health outcomes for people affected by HIV/AIDS and viral hepatitis by serving state, territorial, and local health department staff.
Work here?Claim your company
Simplify's take
What believers are saying
- NASTAD launched Relink HIV Pathways to Care with Gilead in February 2026.
- It is recruiting Hepatitis Advocacy Consultants through November 10, 2026.
- October 2026 ADAP Watch gives states timely cost-containment intelligence during rising drug costs.
What critics are saying
- CDC funding instability is stripping direct HIV-prevention grants from CBOs in 2026.
- NASTAD warned September 2026 state pass-through gaps will leave providers unfunded for months.
- If federal HIV funding shifts permanently to states, NASTAD loses influence and relevance.
What makes NASTAD unique
- NASTAD is the national HIV and hepatitis policy hub for state health directors.
- Its CDC-funded CBA role and Gilead-backed Relink program embed it in government systems.
- Its ADAP Watch and HepTAC platforms convert program data into operational guidance.
Help us improve and share your feedback! Did you find this helpful?